Abstract Number: 2025 • 2015 ACR/ARHP Annual Meeting
Modification of Structural Lesions on Magnetic Resonance Imaging By Etanercept: A 12-Week Randomized Placebo-Controlled Trial
Background/Purpose: Modification of structural lesions by anti-TNF therapy has not been demonstrated in a randomized placebo (PBO)-controlled trial. The Spondyloarthritis Research Consortium of Canada (SPARCC)…Abstract Number: 2026 • 2015 ACR/ARHP Annual Meeting
A Novel Technique for Quantifying Synovial Enhancement of Temporomandibular Joints from Mris of Patients with Juvenile Idiopathic Arthritis
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) commonly affects the temporomandibular joints (TMJ) and may cause growth disturbance, functional limitation and facial deformity. Early diagnosis and management…Abstract Number: 2027 • 2015 ACR/ARHP Annual Meeting
Development of a Dual Energy Computed Tomography Scoring System for Measurement of Urate Deposition in Gout
Development of a Dual Energy Computed Tomography Scoring System for Measurement of Urate Deposition in Gout Background/Purpose: Dual energy computed tomography (DECT) can visualize urate…Abstract Number: 2028 • 2015 ACR/ARHP Annual Meeting
Contribution of 18f-Fluoro-Dexoxyglucose Positron Emission Tomography for the Diagnosis of Polymyalgia Rheumatica: A Controlled Study
Background/Purpose: Polymyalgia rheumatica (PMR) is a frequent inflammatory condition in elderly people. The place of imaging becomes important for positive and differential diagnosis like malignancy…Abstract Number: 2029 • 2015 ACR/ARHP Annual Meeting
Fever of Unknown Origin (FUO) and Inflammation of Unknown Origin (IUO): Is 18f-FDG-PET/CT a Useful First Line Diagnostic Strategy?
Background/Purpose: FUO and IUO are rare but diagnostically challenging clinical problems. Because of the abundance of differential diagnoses, a generally accepted diagnostic guideline has not…Abstract Number: 2030 • 2015 ACR/ARHP Annual Meeting
MRI Changes Associated with Neurological Compromise in Acute Pyogenic Vertebral Osteomyelitis: A Retrospective Study of 121 Patients
Background/Purpose: Vertebral osteomyelitis is a rare but potentially severe disease: previous works have estimated that neurological complications occurred in up to 59% cases. However, these works…Abstract Number: 2031 • 2015 ACR/ARHP Annual Meeting
Tuberculosis in Patients Treated with Biological Drugs
Background/Purpose: Opportunistic infections are a major risk in with biological drugs therapy, being tuberculosis (TB) one of the most relevant. Objectives: evaluate the frequency of…Abstract Number: 2032 • 2015 ACR/ARHP Annual Meeting
Chaperonin Protein 14-3-3eta, Cyclic Citrullinated Peptide Antibody, and Rheumatoid Factor in the Differential Diagnosis of Chikungunya Arthritis Versus Rheumatoid Arthritis
Background/Purpose: Chikungunya fever virus (CHIK) is emerging in the western hemisphere as a mosquito-borne, acute onset arthritis. The majority of cases progress to persistent moderate…Abstract Number: 2033 • 2015 ACR/ARHP Annual Meeting
Clinical Manifestations Associated with Peripheral Joint Involvement in Patients with Acute Chikungunya Virus Infection
Background/Purpose: Chikungunya virus (CHIKV) infection causes an acute febrile illness usually accompanied by severe polyarthralgia and polyarthritis. Previous studies have shown that older age, female…Abstract Number: 2034 • 2015 ACR/ARHP Annual Meeting
Nontuberculous Mycobacterial Diseases Do Not Cause Positive Autoantibody Testing, Results from a Tertiary Pulmonary Care Center
Background/Purpose: National Jewish Health (NJH) is a tertiary referral center for pulmonary and immunologic disease. The infectious disease division at NJH specializes in the care…Abstract Number: 2035 • 2015 ACR/ARHP Annual Meeting
Clinical Characteristics and Outcomes of Polyarticular Septic Arthritis
Background/Purpose: Polyarticular septic arthritis (polySA) is rare, but clinically important, with reported mortality rates approaching 30% even with appropriate therapy. Little is known regarding how…Abstract Number: 2036 • 2015 ACR/ARHP Annual Meeting
Infliximab Versus Adalimumab in Severe Uveitis: Multicenter Study from the French Uveitis Network
Background/Purpose: Anti-tumour necrosis factor (TNF) molecules have become a valuable addition to the therapeutic armamentarium for patients with severe uveitis. However, direct comparison of safety…Abstract Number: 2037 • 2015 ACR/ARHP Annual Meeting
Rheumatic Manifestations May be the First Clinical Presentation of Arterial Calcification Due to CD73 Deficiency
Background/Purpose: ACDC is a hereditary ectopic mineralization syndrome caused by mutations in the NT5E gene that encodes CD73. CD73 is a membrane bound 5'…Abstract Number: 2038 • 2015 ACR/ARHP Annual Meeting
Adalimumab in Patients with Active, Noninfectious Uveitis Using High-Dose Corticosteroids
Background/Purpose: Corticosteroids, currently the mainstay of uveitis treatment, are associated with adverse events and are not always fully effective. Multiple reports describe the use of…Abstract Number: 2039 • 2015 ACR/ARHP Annual Meeting
Effect of Adalimumab on Visual Functioning (VFQ-25) in Visual-1 Trial Patients with Non-Anterior Non-Infectious Uveitis
Background/Purpose: To compare the effects of adalimumab and placebo on the National Eye Institute Visual Functioning Questionnaire 25 (VFQ-25) in subjects requiring high dose corticosteroids…
ACR Meeting Abstracts